Skip to main content
SpringerLink
Log in
Book cover

Antiepileptic Drug Interactions pp 307–317Cite as

Antimicrobials

  • Chapter
  • First Online:

  • 1428 Accesses

Abstract

Phenobarbital Phenobarbital enhances the metabolism of chloramphenicol and can decrease plasma chloramphenicol levels by 70–95 % 1.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Bloxham RA, Durbin GM, Johnson T, Winterborn MH. Chloram­phenicol and phenobarbitone – a drug interaction. Arch Dis Childhood. 1979;54:76–7.

    Article  CAS  Google Scholar 

  2. Krasinski K, Kusmiesz H, Nelson JD. Pharmacologic interactions among chloramphenicol, phenytoin and phenobarbital. Pediatr Infect Dis. 1982;1:232–5.

    Article  PubMed  CAS  Google Scholar 

  3. Randinitis EJ, Alvey CW, Koup JR, Rausch G, Abel R, Bron NJ, Hounslow NJ, Vassos AB, Sedman AJ. Drug interactions with clinafloxacin. Antimicrob Agents Chemother. 2001;45:2543–52.

    Article  PubMed  CAS  Google Scholar 

  4. Penttila O, Neuvonen PJ, Aho K, Lehtovaara R. Interaction between doxycycline and some antiepileptic drugs. Br Med J. 1974;2:470–2.

    Article  PubMed  CAS  Google Scholar 

  5. Neuvonen PJ, Penttila O, Lehtovaara R, Aho K. Effects of antiepileptic drugs on the elimination of various tetracycline derivatives. Eur J Clin Pharmacol. 1975;9:147–54.

    Article  PubMed  CAS  Google Scholar 

  6. Acocella G, Bonollo L, Mainardi M, Margaroli P, Nicolis FB. Kinetic studies on rifampicin. III. Effect of phenobarbital on the half-life of the antibiotic. Tijdschr Gastroenterol. 1974;17:151–8.

    PubMed  CAS  Google Scholar 

  7. Eradiri O, Jamali F, Thomson ABR. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn’s disease. Biopharm Drug Dispos. 1988;9:219–27.

    Article  PubMed  CAS  Google Scholar 

  8. Reigelman S, Rowland M, Epstein WL. Griseofulvin-phenobarbital interaction in man. J Am Med Assoc. 1970;213:426–31.

    Article  Google Scholar 

  9. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, Schentag JJ. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther. 1991;49:420–5.

    Article  PubMed  CAS  Google Scholar 

  10. Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, Pappagianis D, Stevens DA. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14:165–74.

    Article  PubMed  CAS  Google Scholar 

  11. Bonay M, Jonville-Bera AP, Diot P, Lemarie E, Lavendier M, Autret E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf. 1993;9:309–11.

    Article  PubMed  CAS  Google Scholar 

  12. Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de Velde V, Mannens G, Edwards DJ. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than 10-fold by phenytoin. Clin Pharmacol Ther. 1995;58:617–24.

    Article  PubMed  CAS  Google Scholar 

  13. Krishna G, Sansone-Parsons A, Kantesaria B. Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men. Curr Med Res Opin. 2007;23:1415–22.

    Article  PubMed  CAS  Google Scholar 

  14. Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A. Coadministration or voriconazole and phenytoin: pharmacokinetic interaction, safety, and tolerance. Br J Clin Pharmacol. 2003;56 (Suppl 1):37–44.

    Article  PubMed  CAS  Google Scholar 

  15. Lanchote VL, Garcia FS, Dreossi SAC, Takayanagui OM. Pharma­cokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis. Ther Drug Monit. 2002;24:338–45.

    Article  PubMed  CAS  Google Scholar 

  16. Luder PJ, Siffert B, Witassek F, Meister F, Bircher J. Treatment of hydatid disease with high oral doses of mebendazole. Long-term follow-up of plasma mebendazole levels and drug interactions. Eur J Clin Pharmacol. 1986;31:443–8.

    Article  PubMed  CAS  Google Scholar 

  17. Bittencourt PRM, Garcia CM, Martins R, Fernandes AG, Dieckmann HW, Jung W. Phenytoin and carbamazepine decrease oral bioavailability of praziquantel. Neurology. 1992;42:492–6.

    Article  PubMed  CAS  Google Scholar 

  18. Wright JM, Stokes EF, Sweeney VP. Isoniazid-induced carbamazepine toxicity and vice versa. A double drug interaction. N Engl J Med. 1982;307:1325–7.

    Article  PubMed  CAS  Google Scholar 

  19. DiCenzo R, Peterson DR, Cruttenden K, Mariuz P, Rezk NL, Hochreiter J, Gelbard H, Schifitto G. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir. Antimicrob Agents Chemother. 2008;52:3035–9.

    Article  PubMed  CAS  Google Scholar 

  20. Dasgupta A, Okhuysen PC. Pharmacokinetic and other interactions in patients with AIDS. Ther Drug Monit. 2001;23:591–605.

    Article  PubMed  CAS  Google Scholar 

  21. Ji P, Damle B, Xie J, Unger SE, Grasela DM, Kaul S. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol. 2008;48:948–56.

    Article  PubMed  CAS  Google Scholar 

  22. Robertson SM, Penzak SR, Lane J, Pau AK, Mican JM. A potential significant interaction between efavirenz and phenytoin: a case report and review of the literature. Clin Infect Dis. 2005;41:e15–8.

    Article  PubMed  Google Scholar 

  23. DiCenzo R, Peterson DR, Cruttenden K, Morse G, Riggs G, Gelbard H, Schifitto G. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4328–31.

    Article  PubMed  CAS  Google Scholar 

  24. Hugen PWH, Burger DM, Brinkman K, ter Hofstede HJM, Schuuman R, Koopmans PP, Hekster YA. Carbamazepine-indinavir interaction causes antiretroviral failure. Ann Pharmacother. 2000;34:465–70.

    Article  PubMed  CAS  Google Scholar 

  25. Langdon G, Davis J, Layton G, Chong C, Weissgerber G, Vourvahis M. Effects of ketoconazole and valproic acid on the pharmacoki­netics of the next-generation NNRTI lersivirine (UK-453,061) in healthy adult subjects. Br J Clin Pharmacol. 2012;73(5):768–75.

    Article  PubMed  CAS  Google Scholar 

  26. Van der Lee MJ, Dawood L, ter Hofstede HJM, de Graaff-Teulen MJA, van Ewijk-Beneken-Kolmer EWJ, Caliskan-Yassen N, Koopmans PP, Burger DM. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy volunteers. Clin Pharmacol Ther. 2006;80:159–68.

    Article  PubMed  Google Scholar 

  27. Wong MC, Suite ND, Labar DR. Seizures in human immunodeficiency virus infection. Arch Neurol. 1990;47:640–2.

    Article  PubMed  CAS  Google Scholar 

  28. Lim ML, Min SS, Eron JJ, Bertz RJ, Robinson M, Gaedigk A, Kashuba AD. Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 induction. J Acquir Immune Defic Syndr. 2004;36(5):1034–40.

    Article  PubMed  CAS  Google Scholar 

  29. L’Homme RF, Dijkema T, van der Ven AJ, Burger DM. Brief report: enzyme inducers reduce the elimination half-life after a single dose of nevirapine in healthy women. J Acquir Immune Defic Syndr. 2006;43:193–6.

    Article  PubMed  Google Scholar 

  30. van Luin M, Colbers A, Verwey-van Wissen CP, van Ewijk-Beneken-Kolmer EW, van der Kolk M, Hoitsama A, da Silva HG, Burger DM. The effect of raltegravir on the glucuronidation of lamotrigine. J Clin Pharmacol. 2009;49:1220–7.

    Article  PubMed  Google Scholar 

  31. Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003;56:526–36.

    Article  PubMed  CAS  Google Scholar 

  32. Kellinghaus C, Engbrine C, Kovac S, Moddel G, Boesebeck F, Fischera M, Anneken K, Klonne K, Reichelt D, Evers S, Husstedt IW. Frequency of seizures and epilepsy in neurological HIV-infected patients. Seizure. 2008;17:27–33.

    Article  PubMed  CAS  Google Scholar 

  33. Burger DM, Meenhorst PL, Mulder JW, Kraaijeveld CL, Koks CH, Bult A, Beijnen JH. Therapeutic drug monitoring of phenytoin in patients with acquired immunodeficiency syndrome. Ther Drug Monit. 1994;16:616–20.

    Article  PubMed  CAS  Google Scholar 

  34. Lertora JJ, Rege AB, Greenspan DL, Akula S, George WJ, Hyslop NE, Agrawal KC. Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 1994;56:272–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCL-Institute of Neurology Department of Clinical and Experimental Epilepsy, Queen Square, London, London

    P. N. Patsalos

  2. Epilepsy Society Chalfont Centre for Epilepsy, Chalfont St Peter, Buckinghamshire, UK

    P. N. Patsalos

Authors
  1. P. N. Patsalos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Patsalos, P.N. (2013). Antimicrobials. In: Antiepileptic Drug Interactions. Springer, London. https://doi.org/10.1007/978-1-4471-2434-4_56

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-2434-4_56

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-2433-7

  • Online ISBN: 978-1-4471-2434-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation